Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
Condition(s):Pyoderma; Pyoderma Gangrenosum; Pyoderma Vegetans; Pyoderma Gangrenosum Surrounding Surgical StomaLast Updated:March 20, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Pyoderma; Pyoderma Gangrenosum; Pyoderma Vegetans; Pyoderma Gangrenosum Surrounding Surgical StomaLast Updated:March 20, 2023Completed
Condition(s):Colorectal Cancer; ImmunotherapyLast Updated:May 21, 2021Recruiting
Condition(s):Lymphoma, Non-Hodgkin; Lymphoma, T-CellLast Updated:September 28, 2022Recruiting
Condition(s):EBV InfectionLast Updated:September 9, 2021Recruiting
Condition(s):Infusion Reaction; Monoclonal AntibodyLast Updated:November 2, 2022Recruiting
Condition(s):Metastatic Colorectal CancerLast Updated:January 23, 2018Unknown status
Condition(s):Breast CancerLast Updated:October 23, 2019Completed
Condition(s):Lymphoepithelioma-Like CarcinomaLast Updated:June 12, 2020Unknown status
Condition(s):Melanoma; Urological CancerLast Updated:October 22, 2019Unknown status
Condition(s):Primary Immune Thrombocytopenia (ITP)Last Updated:February 8, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.